BioStock: Abliva has strengthened its position during 2020
For Abliva, the first half of the year has meant a continuation of the process that began in autumn 2019, when the company decided to focus its work on primary mitochondrial diseases. In 2020, its position has also been strengthened through a rights issue and the addition of well-regarded life science investor Hadean Ventures to the owner list. BioStock contacted CEO Erik Kinnman to hear more about the past six months and what he expects from the rest of 2020.
Read the full interview at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se